Virios Therapeutics, Inc. (VIRI)

Market Cap	4.70M
Revenue (ttm)	n/a
Net Income (ttm)	-4.68M
Shares Out	27.76M
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	306,789
Open	0.161
Previous Close	0.157
Day's Range	0.160 - 0.172
52-Week Range	0.151 - 1.040
Beta	1.58
Analysts	Buy
Price Target	0.60 (+254.61%)
Earnings Date	Nov 11, 2024

About VIRI

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly kn...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 17, 2020
• Employees: 4
• Stock Exchange: NASDAQ
• Ticker Symbol: VIRI
• Website: https://www.virios.com

Analyst Forecast

According to 2 analysts, the average rating for VIRI stock is "Buy." The 12-month stock price forecast is $0.6, which is an increase of 254.61% from the latest price.

Price Target

$0.6

(254.61% upside)

Analyst Consensus: Buy